How to Buy Gilead Sciences Stock
Gilead Sciences Inc
Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Gilead Sciences stock last closed at $104.33, down 0.2% from the previous day, and has increased 55.83% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.57 percentage points. Gilead Sciences stock is currently +68.08% from its 52-week low of $62.07, and -13.03% from its 52-week high of $119.96.
There are currently 1.25B GILD shares outstanding. The market value of GILD is $129.93B. In the last 24 hours, 6.6M GILD shares were traded.
How to Buy Gilead Sciences Stock
Not sure how to invest in Gilead Sciences stock? Here's how.
- Decide where to buy Gilead Sciences stock: You need to pick an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you decide where to buy Gilead Sciences stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Choose your method of payment and add your details.
- Analyze Gilead Sciences stock: The Gilead Sciences ticker symbol is GILD. Is Gilead Sciences stock a good investment? Should you buy shares of GILD? How do GILD's underlying business fundamentals look? Do top analysts think Gilead Sciences is a good buy? Why has GILD's stock price moved recently? (Hint: Our stock analysis website can help you figure out if GILD is a good stock to buy).
- Execute your GILD purchase: Decide if you will purchase GILD shares at the current market price or use a limit order to buy GILD shares at a specific price.
- Keep tabs on your investment in GILD: Create a watchlist to track your position in Gilead Sciences shares.
Step 1: Decide where to buy Gilead Sciences stock
You will need an online brokerage account to access the NASDAQ market and buy GILD stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Technology to Real Estate, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked the right brokerage, you need to fill out some personal details so you can invest in GILD today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to open a new brokerage account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've filled out your info on one of the most highly reviewed stock market apps, you can securely and quickly fund your account:
Watch the tutorial below to see the process of transferring funds into your new investment account.
Step 4: Analyze Gilead Sciences stock
After you have decided on the best place to buy Gilead Sciences stock, it's crucial to research their stock prior to buying, so you truly wrap your head around the risk and opportunity.
Gilead Sciences stock data
Gilead Sciences Overview
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on GILD's stock page.
Is GILD stock undervalued?
You can use many financial metrics, analyses, models, and charts to gauge GILD's intrinsic value.
Using relative valuations measures:
- GILD may be overvalued based on its P/E ratio of 274.55x, relative to Drug Manufacturers - General industry P/E ratio of 51.51x
- GILD may be overvalued based on its P/B ratio of 6.72x, relative to Drug Manufacturers - General industry P/B ratio of 5.94x
- GILD could be overvalued based on its PEG ratio of 1.47x
You can access additional valuation analysis on GILD's stock here.
How do GILD Financials look?
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the GILD balance sheet.
- GILD's operating cash flow of $10.83B allows it to safely service it's debt of $26.71B.
Negative Health Checks:
- Total GILD debt is higher than 5 years ago, relative to shareholder equity.
- GILD has a relatively high debt to equity ratio of 2.06.
- There are more long-term liabilities than short-term assets on the GILD balance sheet.
- GILD earnings of $1.67B is not enough to cover its interest payments.
- GILD profit margin has gone down from 20.9% to 1.7% in the past year.
Is it a good time to buy Gilead Sciences stock, according to analysts?
Out of 19 Wall Street analysts who monitor GILD, the consensus analyst rating on Gilead Sciences is a Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Latest GILD Analyst Forecasts
James Shin, a top 29% analyst from Deutsche Bank upgrades GILD to a strong buy rating and raises their GILD price target from $80.00 to $120.00, on Feb 18, 2025.
Deutsche Bank's James Shin upgraded their rating on Gilead Sciences (NASDAQ: GILD) from Hold to Strong Buy on 2025/02/18. The analyst also raised their price target by 50% from $80 to $120.
Gilead Sciences reported its Q4 and FY 2024 earnings on 2025/02/11.
Shin predicted that the company's primary HIV product would continue to fuel stable revenue growth well into the 2030s.
According to the analyst, the launch of lenacapavir for pre-exposure prophylaxis in the summer of 2025 is the Street's main near-term focus, pointing out that the launch should more than offset Descovy's patent expiration in 2031.
By FY 2033, Shin told investors to expect Gilead Sciences' HIV treatment portfolio, including long-acting orals and injectables, to generate $19B, enough to cover Biktarvy's 2033 patent cliff.
The company's scarcity value is enhanced by its "optionality" when compared to biopharma peers that are either approaching or currently dealing with patent cliffs, the analyst noted.
Footnotes
Lenacapavir is an antiretroviral medication used to treat HIV/AIDS. It is part of a class of drugs known as capsid inhibitors, which work by disrupting the protective capsid layer surrounding HIV's genetic material.
Descovy is a prescription medication used for both the treatment and prevention of HIV.
Biktarvy is a prescription medication used to treat HIV-1 infection.
Earnings Report
Gilead Sciences reported:
For Q4 2024:
- EPS of $1.90, which beat the Zacks Consensus Estimate of $1.67 and, by 10%, Q4 2023’s $1.72.
- Revenue of $7.57B, which beat the Zacks Consensus Estimate by 7.27% and, by 6%, Q4 2023’s $7.12B.
For FY 2024:
- EPS of $4.62, down 31% Y/Y.
- Revenue of $28.75B, up 6% Y/Y.
For FY 2025, management guided:
- EPS of $7.70 to $8.10.
Chairman & CEO Daniel O’Day commented: “Gilead delivered another exceptionally strong Q4 and FY, with growth in our base business product sales of 8% for 2024 and 13%Y/Y for Q4.
“From this foundation of commercial strength, we are planning for the potential launch of lenacapavir for HIV PrEP in Summer 2025, with its unique opportunity to extend the reach of HIV prevention.
“This potential in HIV, along with our strong and diverse portfolio, and improved operational efficiencies, positions Gilead to deliver increasing patient impact and compelling shareholder returns in the years ahead.”
Brian Abrahams, a bottom 3% analyst from RBC Capital maintains GILD with a hold rating and raises their GILD price target from $84.00 to $90.00, on Feb 12, 2025.
Salveen Richter, a bottom 14% analyst from Goldman Sachs maintains GILD with a hold rating and raises their GILD price target from $85.00 to $96.00, on Feb 12, 2025.
Evan Seigerman, a bottom 19% analyst from BMO Capital maintains GILD with a buy rating and raises their GILD price target from $110.00 to $115.00, on Feb 12, 2025.
Joseph Catanzaro, a bottom 3% analyst from Piper Sandler maintains GILD with a strong buy rating and raises their GILD price target from $105.00 to $110.00, on Feb 12, 2025.
You can dive deeper into what analysts are saying on the Gilead Sciences stock forecast page.
GILD Momentum
GILD Revenue
Last year, GILD earnings were $480.00M. In the past 5 year, GILD's earnings have increased by -38.27% per year. This was slower than the Drug Manufacturers - General industry average of 0.89%.
Last year, GILD revenue was $28.75B. In the past 5 year, GILD's revenue has gone up by 5.08% per year. This was slower than the Drug Manufacturers - General industry average of 9.15%.
Dive into GILD's earnings and revenue performance here.
What are GILD insiders up to?
In the last year, insiders at GILD have sold more shares than they have bought.
Andrew D. Dickinson, Chief Financial Officer of GILD, was the latest GILD insider to sell. They sold $266,000.00 worth of GILD stock on Apr 15, 2025.
Get more info about who owns GILD stock here.
Can I get consistent income from GILD stock?
Gilead Sciences pays a dividend of 2.97%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.51%. If you owned $1,000 worth of GILD stock, you would have been paid $29.71 last year.
Gilead Sciences dividend payments have consistently grown over the past decade and have remained stable.
Find more info about Gilead Sciences dividend yield and history here.
GILD Social Trading Data
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your GILD purchase
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually fine. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a given price, place a limit order.
Press the Open Trade button and your broker will execute your order.
If you want additional assistance buying stocks on eToro, click the helpful video below:
Step 6: Keep tabs on your investment in GILD
Now that you own some GILD stock, you'll want to stay up-to-date on your new stock purchase.
Put GILD on a watchlist to track your GILD stock.
GILD Feed
How to Buy Stock in Gilead Sciences
To reiterate, here are the 6 steps to buy stock in Gilead Sciences:
- Decide where to buy Gilead Sciences stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Analyze Gilead Sciences stock
- Execute your GILD purchase
- Keep tabs on your investment in GILD
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get updates on your investment in Gilead Sciences, create your watchlist below.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.